The rapid development of the manufacturing industry has made China's cutting tool market have great potential for development. The total amount is expected to exceed that of Germany, the United States and Japan, providing a sufficient operating space for the adjustment and development of China's tool industry.

We believe that although the global economy will have cyclical changes and turbulence. However, the large pattern of manufacturing transfer to China is based on the objective needs of resource allocation and allocation in the context of globalization, and there will be no reversal. At present, the output value of China's manufacturing industry is generally between Japan and the United States, but at the level of physical output, it has greatly exceeded Japan and the United States. China has ranked first in the world for machine tools consumption for five consecutive years.

In 2007, China's machine tool ownership reached 5 million units, far exceeding the developed countries, and the number of CNC machine tools reached 600,000 units. The number is comparable to that of Japan and the United States, but the grade is low. In developed countries, the use of efficient tools to harness the potential of digital manufacturing technology has become a consensus. Annual tool consumption is about 50% of machine tool consumption. In China, tool consumption is only 20% of machine tool consumption. It shows that in China's tool consumption, cheap and inefficient traditional knives still dominate, machine tool functions are far from full, and the potential of manufacturing to improve labor productivity is great. This is not only the gap between China's tool industry, but also the use of China's tool industry. The golden key to developing the Chinese tool market is to develop modern and efficient tools to replace cheap, inefficient traditional tools.

Through the above analysis, we can clearly see that the biggest opportunity facing Chinese tool companies is that at our doorstep, there is one of the world's largest tool markets, providing sufficient space for our development. However, we are faced with severe challenges. The modern and efficient tools that the market needs, we are developing very slowly, unable to meet the needs of the manufacturing industry, and have to import a lot. Traditional standard knives that do not meet the needs of modern manufacturing development are blindly developed, and the total amount is out of control, resulting in a passive situation of overproduction and low-price marketing. Therefore, there is only one way out for China's tool industry, that is, to develop modern and efficient tools, to achieve structural adjustment and industrial upgrading, and to get rid of the low-level and repetitive development path.

Since the beginning of the new century, the Chinese tool industry has begun the process of structural adjustment and industrial upgrading, but the pace of progress is too slow. Faced with the challenges of the new economic situation, the vast number of industry enterprises must have a sense of urgency and accelerate the pace of adjustment. Develop a large market for potential Chinese tools. To achieve this, the scale of the Chinese tool market will exceed that of Japan, the United States and Germany. In doing so, not only will China's tool industry grow and develop, but China's manufacturing industry will greatly improve production efficiency and competitiveness through the extensive adoption of modern and efficient tools. The benefits obtained are much higher than the tool industry and are a win-win situation.

Wy-14,643 (Pirinixic acid) is a moderate agonist of PPARα and PPARγ with IC50 of 36.5 μM and 53.7 μM, respectively. IC50 value: 36.5 μM (for PPARα), 53.7 μM (for PPARγ) [2] Target: PPARα, PPARγ in vitro: Wy-14,643 is a moderate agonist of PPARα and PPARγ, leads to low micromolar active balanced dual agonists of PPARα and PPARγ.  The aliphatic substitution in α-position of the carboxylic acid head group of Wy-14,643 leads to more potent dual PPARα/γ agonists with a significant preference towards PPARα. Wy-14,643 exhibits beneficial effects in various inflammation-related processes in a slow, long-termed fashion. [2] in vivo: Wy-14,643 shows beneficial effects in animal models of inflammation and cardiovascular diseases that rely on slow-acting transcriptional events modulating protein expression. Wy-14,643 reduces the expression and production of cytokines, adhesion molecules, inducible NO synthase, heme oxygenase-1, and cyclooxygenase-2. Wy-14,643 inhibits human aldose reductase activity and increased uncoupling of oxidative phosphorylation in isolated mitochondria.



WY-14643

WY-14643,WY-14643 In Stock,Pirnixicacid In Stock,Cas 50892-23-4 WY-14643 In Stock

Jinan Meigao Biopharmaceutical Technology Co., Ltd. , http://www.meigaobiopharma.com

Posted on